Beta‐adrenoceptor responses to inhaled salbutamol in the elderly.

Lipworth, BJ; Tregaskis, B; McDevitt, DG

doi:10.1111/j.1365-2125.1989.tb03568.x

Cited by 15 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, reported data are in favor of the hypothesis that ß 2 -receptor functioning is maintained in the elderly, although one study reported a decrease in the chronotropic cardiovascular response to isoprenaline in healthy elderly subjects [23]. However, two other placebo-controlled studies, evaluating dosedependent increases in finger tremor and heart rate in younger and older subjects to cumulative doses of inhaled salbutamol following pretreatment with propanolol (a ß 1 -and ß 2 -antagonist), showed no evidence for a decrease in ß 2 -adrenoceptor activity in the elderly [24,25].…”

Section: Discussionmentioning

confidence: 99%

Acute Effects of Nebulized Salbutamol on Resting Energy Expenditure in Patients with Chronic Obstructive Pulmonary Disease and in Healthy Subjects

Creutzberg¹,

Schols²,

Bothmer-Quaedvlieg³

et al. 1998

Respiration

View full text Add to dashboard Cite

This study investigated the contribution of a single dose of salbutamol by nebulizer to the increased resting energy expenditure (REE) frequently found in patients with chronic obstructive pulmonary disease (COPD) (n = 22), in comparison with a younger (n = 15) and an older healthy (n = 10) control group. The rise in REE after nebulization of 5 mg salbutamol was significantly higher in younger (11.4%) compared to older healthy subjects (5.7%; p < 0.05) and patients with COPD (4.2%; p < 0.001), which also accounted for the increase in heart rate and the drop in the respiratory quotient. No differences in metabolic effects were found between older control subjects and patients with COPD. In conclusion, despite significant improvements in FEV₁ and airway resistance, a significant rise in REE was observed in patients with COPD after nebulization of salbutamol. The metabolic effects of salbutamol were however not sufficient to explain totally the elevated REE seen in these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Acute Effects of Nebulized Salbutamol on Resting Energy Expenditure in Patients with Chronic Obstructive Pulmonary Disease and in Healthy Subjects

Creutzberg¹,

Schols²,

Bothmer-Quaedvlieg³

et al. 1998

Respiration

View full text Add to dashboard Cite

show abstract

“…Lastly, as beta 2 ‐agonists can increase heart rate and ventilation, cardiac and respiratory muscle work may also contribute to the beta 2 ‐agonist‐induced increase in metabolic rate.…”

Section: Mechanisms Underlying the Lipolytic And Metabolic Actions Ofmentioning

confidence: 99%

Anabolic and lipolytic actions of beta₂‐agonists in humans and antidoping challenges

Hostrup

Jacobson

Jessen

et al. 2020

Drug Testing and Analysis

View full text Add to dashboard Cite

Inhaled beta 2 -adrenoceptor agonists (beta 2 -agonists) are among the most used substances in competitive sports. The 2020 Prohibited List issued by the World Anti-Doping Agency restricts use of all selective and non-selective beta 2 -agonists in-and out-of competition with few exemptions. Formoterol, salbutamol, and salmeterol are allowed by inhalation within defined dosing limits. These restrictions are in place because supratherapeutic use of beta 2 -agonist has the potential to be anabolic and to enhance performance, as well as due to potential side effects. Despite substantial documentation that beta 2 -agonists exert anabolic and lipolytic actions, these actions are not widely recognized. Furthermore, a common misconception is that the inhaled route does not exert these effects. However, given the high relative systemic bioavailability via the inhaled route, inhalation at high doses can also exert anabolic and lipolytic actions. In this review, we highlight the anabolic and lipolytic actions beta 2agonists can exert, regardless of the type of beta 2 -agonist and the route of administration. The doses needed to provide such effects are also associated with adverse effects and would in most cases be detected in routine doping control. Notwithstanding, the beta 2 -agonist regulations are associated with some challenges and given their ability to induce muscle growth and to enhance performance, it is important to continue developing effective detection strategies to prevent potential misuse of beta 2 -agonists while allowing treatment of asthmatic subjects without causing adverse side effects or ergogenic actions. K E Y W O R D Sanabolic, beta agonists, doping, hypertrophy, muscle growth

show abstract

“…It was reported that pi-adrenergic receptor responsiveness is reduced with aging,42 whereas p2-receptor responsiveness appeared to remain preserved in elderly compared with young ~u b j e c t s .~~~ 43,44 Although no statistically significant difference in in vivo pulmonary or in vitro T lymphocyte p2-receptor response to terbutaline was seen in elderly over young asthmatics, trends toward a dampened response in vivo and in vitro, as well as reduced cardiovascular pi-receptor response, existed in our elderly subjects. Overall, our in vitro results are consistent with the in vivo observations.…”

Section: Discussionmentioning

confidence: 98%

In Vivo and In Vitro β₂‐Adrenergic Receptor Responsiveness in Young and Elderly Asthmatics

Hamelin,

Blouin,

Wolf

et al. 1992

Pharmacotherapy

View full text Add to dashboard Cite

This pilot study was undertaken to characterize age‐related alterations in airway and metabolic β2‐adrenergic receptor response using terbutaline as a probe. A single dose of terbutaline 0.007 mg/kg was administered subcutaneously to 10 young (range 20–35 yrs) and 10 elderly (range 60–73 yrs) men and women with asthma. β‐Receptor function was assessed by serial pulmonary function tests, heart rate, blood pressure, plasma potassium, glucose, insulin, and catecholamine levels, and in vitro 3′, 5′‐cyclic adenosine monophosphate (cAMP) production of pure T lymphocytes. The trend was for lung β2‐receptor response (bronchodilation) and T lymphocyte cAMP production to be lower in elderly than in young asthmatics, but differences did not reach statistical significance. Elderly subjects' β1‐adrenergic receptor responsiveness (systolic blood pressure) was also dampened. These data suggest that T lymphocyte stimulation does reflect pulmonary β2‐receptor response. Whether elderly asthmatics require and tolerate higher dosages of parenteral terbutaline than younger asthmatics deserves further study.

show abstract

Beta‐adrenoceptor responses to inhaled salbutamol in the elderly.

Cited by 15 publications

References 21 publications

Acute Effects of Nebulized Salbutamol on Resting Energy Expenditure in Patients with Chronic Obstructive Pulmonary Disease and in Healthy Subjects

Acute Effects of Nebulized Salbutamol on Resting Energy Expenditure in Patients with Chronic Obstructive Pulmonary Disease and in Healthy Subjects

Anabolic and lipolytic actions of beta₂‐agonists in humans and antidoping challenges

In Vivo and In Vitro β₂‐Adrenergic Receptor Responsiveness in Young and Elderly Asthmatics

Contact Info

Product

Resources

About

Beta‐adrenoceptor responses to inhaled salbutamol in the elderly.

Cited by 15 publications

References 21 publications

Acute Effects of Nebulized Salbutamol on Resting Energy Expenditure in Patients with Chronic Obstructive Pulmonary Disease and in Healthy Subjects

Acute Effects of Nebulized Salbutamol on Resting Energy Expenditure in Patients with Chronic Obstructive Pulmonary Disease and in Healthy Subjects

Anabolic and lipolytic actions of beta2‐agonists in humans and antidoping challenges

In Vivo and In Vitro β2‐Adrenergic Receptor Responsiveness in Young and Elderly Asthmatics

Contact Info

Product

Resources

About

Anabolic and lipolytic actions of beta₂‐agonists in humans and antidoping challenges

In Vivo and In Vitro β₂‐Adrenergic Receptor Responsiveness in Young and Elderly Asthmatics